Boston Scientific announces results for third quarter 2026

Boston Scientific reported Q3 2026 sales of $5.138 billion, up 1.5% year over year, while adjusted EPS fell to $0.73 from $0.75 and GAAP EPS declined to $0.40 from $0.51. The company forecasts Q4 sales down 1%–3% on a reported and organic basis, and full-year 2026 adjusted EPS of $3.16–$3.18, with reported sales growth of approximately 4.25% and organic growth of 3.75%. Management described the year as challenging and cited its response to the August 2026 cybersecurity incident; the release also highlighted FDA clearances, clinical-trial enrollment and an AI-focused collaboration with Heartflow.

Analysis

BSX: near-term execution risk outweighs pipeline optionality. The key signal is not simply slower growth: the Q4 contraction outlook points to a weak exit rate after a year in which cybersecurity disruption may have impaired execution. If operations normalize, sales could recover; if not, lower utilization, delayed procedures, or customer workarounds could make disruption persistent and expose share to competitors such as Abbott and Medtronic. The steep gap between GAAP and adjusted results, alongside weaker reported gross profit despite higher sales, also makes underlying earnings quality and margin recovery important diligence items—not just adjusted EPS.

There is internal dispersion beneath the consolidated result: Neuromodulation is a relative bright spot, while Urology and Endoscopy are contracting. That argues against treating the product pipeline as a broad-based near-term offset. The Heartflow collaboration offers strategic validation of AI-assisted PCI planning, but no disclosed economics yet support assigning material value to it; HTFL may benefit from validation, with monetization still unproven. CPT coding changes effective in 2028 are a longer-dated adoption catalyst, not a 2026 earnings fix.

Over days, the call’s explanation of the Q4 decline and cyber recovery path matters more than product announcements. Over 1–3 months, watch sales recovery, gross-margin trajectory, and whether guidance is revised. Over 6–18 months, successful launches and reimbursement-supported adoption could restore growth. The contrarian risk to a bearish read is that current weakness is temporary disruption and the strong subsegment/pipeline can reaccelerate results; evidence of recovered operations and improving organic sales would falsify the cautious thesis.

Key Decisions for Investors

• Maintain an underweight bias in BSX rather than making a high-conviction outright short before the earnings call clarifies the Q4 decline. Reassess if management gives a credible operational recovery timeline and segment-level stabilization.
• For a relative-value expression, consider short BSX versus a diversified medtech basket to isolate company execution risk; size modestly until the cybersecurity impact and gross-margin drivers are quantified. Falsify on a clear return to positive organic growth with improving margins.
• Treat HTFL’s collaboration as a watch item, not a standalone long thesis: seek evidence of integration, customer adoption, and commercial economics before underwriting meaningful revenue. Track 2028 CPT implementation as a longer-term catalyst for renal denervation and tibial nerve stimulation, not an immediate catalyst.